行情

CLSN

CLSN

Celsion
NASDAQ

实时行情|Nasdaq Last Sale

1.480
-0.010
-0.67%
交易中 14:20 01/29 EST
开盘
1.500
昨收
1.490
最高
1.560
最低
1.460
成交量
15.05万
成交额
--
52周最高
2.630
52周最低
1.050
市值
3,353.06万
市盈率(TTM)
-4.1272
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLSN 新闻

  • Does Celsion Corporation (NASDAQ:CLSN) Have A High Beta?
  • Simply Wall St..01/20 10:41
  • Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
  • Zacks.01/15 21:34
  • Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
  • Zacks.01/15 13:22
  • Ultragenyx Provides Preliminary Crysvita 2019 Revenues
  • Zacks.01/14 13:53

更多

所属板块

生物技术和医学研究
-0.01%
制药与医学研究
+0.44%

热门股票

名称
价格
涨跌幅

CLSN 简况

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
展开

Webull提供Celsion Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。